Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical evidence

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 407-417

  Balayssac, David ^a,b,c   Ferrier, Jérémy ^a   Descoeur, Juliette ^a   Ling, Bing ^a   Pezet, Denis ^b,c   Eschalier, Alain ^a,b,c   Authier, Nicolas ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

adverse drug reaction; anticancer drug; neuropathy; oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DOCETAXEL; IXABEPILONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; THALIDOMIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; DEMYELINATION; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY;

EID: 79955439425     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.543417     Document Type: Review

References (100)

1. Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006;18(4):321-4 (Pubitemid 44297240)
2. Balayssac D, Cayre A, Authier N, et al. Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. J Peripher Nerv Syst 2005;10(3):301-10 (Pubitemid 41580035)
3. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9-17 (Pubitemid 34119018)
4. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23(3):162-73
5. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35(3):304-11 (Pubitemid 24089653)
6. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13(1):27-46 (Pubitemid 351393018)
7. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986;1(6):421-7 (Pubitemid 17208173)
8. DArcy PF, Griffin JP. Iatrogenic diseases. 3rd edition. OUP, Oxford; 1986
9. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974;80(6):733-7
10. Xiao WH, Bennett GJ. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008;135(3):262-70 (Pubitemid 351330186)
11. Macfarlane BV, Wright A, Benson HA. Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. J Pharm Pharmacol 1997;49(1):97-101 (Pubitemid 27051038)
12. Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 2010;70(14):5870-9
13. Ravula SK, Wang MS, McClain MA, et al. Spatiotemporal localization of injury potentials in DRG neurons during vincristine-induced axonal degeneration. Neurosci Lett 2007;415(1):34-9 (Pubitemid 46356725)
14. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3(6):755-66 (Pubitemid 34649705)
15. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. J Natl Cancer Inst Monogr 1993;(15):107-15
16. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47(9):2486-93 (Pubitemid 17099218)
17. Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/ cisplatin chemotherapy. Eur J Cancer 1997;33(9):1393-9 (Pubitemid 27404896)
18. Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007;13(6):399-403
19. Jerian SM, Sarosy GA, Link CJ Jr, et al. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol Oncol 1993;51(2):277-80 (Pubitemid 24020378)
20. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337-40 (Pubitemid 36152036)
21. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17(11):3403-11 (Pubitemid 29517907)
22. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26(10):1642-9
23. Scuteri A, Nicolini G, Miloso M, et al. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 2006;26(2A):1065-70
24. Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000;21(3):389-93
25. Dougherty PM, Cata JP, Cordella JV, et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004;109(1-2):132-42 (Pubitemid 38479779)
26. Yang IH, Siddique R, Hosmane S, et al. Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration. Exp Neurol 2009;218(1):124-8
27. Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994;51(7):726-9 (Pubitemid 24201893)
28. Authier N, Balayssac D, Marchand F, et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009;6(4):620-9
29. Authier N, Gillet JP, Fialip J, et al. Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res 2000;887(2):239-49 (Pubitemid 32008045)
30. Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007;1168:46-59 (Pubitemid 47320623)
31. Nishida K, Kuchiiwa S, Oiso S, et al. Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci 2008;99(8):1618-25
32. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122(3):245-57 (Pubitemid 43729476)
33. Jin HW, Flatters SJ, Xiao WH, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008;210(1):229-37
34. Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006;201(2):507-14 (Pubitemid 44344243)
35. Shemesh OA, Spira ME. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2010;119(2):235-48
36. Wang MS, Davis AA, Culver DG, et al. Calpain inhibition protects against taxol-induced sensory neuropathy. Brain 2004;127(Pt 3):671-9 (Pubitemid 38295480)
37. Clifford K, Melli G, Cavaletti G, et al. Mechanism of axonal degeneration in paclitaxel-induced neuropathy. Ann Neurol 2009;66:S18
38. Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005;41(8):1117-26 (Pubitemid 40725569)
39. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24(10):1633-42 (Pubitemid 46638788)
40. Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46(1):104-8 (Pubitemid 26156111)
41. Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996;47(1):115-18 (Pubitemid 26243870)
42. Fazio R, Quattrini A, Bolognesi A, et al. Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol 1999;98(6):651-3
43. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005;41(10):1460-6 (Pubitemid 40826471)
44. Trivedi M, Budihardjo I, Loureiro K, et al. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol 2008;4(4):483-500
45. Bosch-Barrera J, Espinos J, Gomez-Ibanez A, et al. Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone. Clin Transl Oncol 2009;11(11):765-7
46. Cardoso F, de Azambuja E, Lago LD. Current perspectives of epothilones in breast cancer. Eur J Cancer 2008;44(3):341-52
47. OConnor OA, Portlock C, Moskowitz C, et al. A multicentre phase II clinical experience with the novel aza-epothilone ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2008;143(2):201-9
48. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25(23):3415-20 (Pubitemid 47310877)
49. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25(23):3421-7 (Pubitemid 47310878)
50. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs [review]. Oncol Rep 2004;11(3):559-95
51. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 1989;25(1):62-4 (Pubitemid 20000800)
52. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54(7):1269-75 (Pubitemid 14003522)
53. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990;66(6):1117-23 (Pubitemid 20310648)
54. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002;13(2):229-36 (Pubitemid 34704974)
55. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 2002;9(2):220-33 (Pubitemid 34261216)
56. Russell JW, Windebank AJ, McNiven MA, et al. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res 1995;676(2):258-67
57. Holmes J, Stanko J, Varchenko M, et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998;46(2):342-51 (Pubitemid 29069619)
58. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006;27(6):992-1002 (Pubitemid 44838955)
59. Alaedini A, Xiang Z, Kim H, et al. Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol 2008;210(2):368-74
60. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982;39(11):719-20 (Pubitemid 12003431)
61. Scott RH, Woods AJ, Lacey MJ, et al. An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Naunyn Schmiedebergs Arch Pharmacol 1995;352(3):247-55
62. Ta LE, Bieber AJ, Carlton SM, et al. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010;6:15
63. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010;3:11
64. Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009;27(8):1243-9
65. Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park) 2000;14(12 Suppl 11):15-20
66. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009;144(3):245-52
67. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008;29(6):1100-6
68. Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009;147(1-3):165-74
69. Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009;458(2):93-5
70. Hill A, Bergin P, Hanning F, et al. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010;10:451
71. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30(4 Suppl 15):5-13 (Pubitemid 37259547)
72. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010;303(11):1037-45
73. Grothey A, Kellermann L, Schmoll HJ. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin (Munich) 2002;97(5):270-7
74. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47 (Pubitemid 30644117)
75. Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005;31(8):591-602 (Pubitemid 41662886)
76. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593-9
77. Corso A, Mangiacavalli S, Varettoni M, et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2009;34(4):471-4
78. Gupta S, Pagliuca A, Devereux S, et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006;91(7):1001 (Pubitemid 44023165)
79. El-Cheikh J, Stoppa AM, Bouabdallah R, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 2008;8(3):146-52
80. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8(4):296-306 (Pubitemid 46551871)
81. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204(1):317-25 (Pubitemid 46330280)
82. Meregalli C, Canta A, Carozzi VA, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010;14(4):343-50
83. Silverman L, Csizmadia V, Kadambi VJ, et al. Model for proteasome inhibition associated peripheral neuropathy. Toxicol Pathol 2006;34(7):S3-S14
84. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005;10(2):107-14 (Pubitemid 40247808)
85. Corso A, Zappasodi P, Barbarano L, et al. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leuk Res 2009;33(9):e145-9
86. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007;69(6):573-81 (Pubitemid 47357264)
87. Kocer B, Sucak G, Kuruoglu R, et al. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. Acta Neurol Belg 2009;109(2):120-6
88. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003;60(5):877-8 (Pubitemid 36297380)
89. Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 2008;79(11):1258-61
90. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62(12):2291-3 (Pubitemid 38787791)
91. Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004;62(12):2288-90 (Pubitemid 38787790)
92. Hamanoue M, Middleton G, Wyatt S, et al. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 1999;14(1):28-40 (Pubitemid 29372853)
93. Empl M, Renaud S, Erne B, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001;56(10):1371-7 (Pubitemid 32455300)
94. George A, Marziniak M, Schafers M, et al. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000;88(3):267-75
95. Dworkin RH, OConnor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
96. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010;11(11):1057-65
97. Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42(17):2893-6 (Pubitemid 44755257)
98. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11(5):509-13 (Pubitemid 30431370)
99. Kim BJ, Park HR, Roh HJ, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 2010;19(8):1097-103
100. OConnor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27(2):95-112